Liraglutide Benefits: What Studies Report

Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed and marketed as a prescription medicine. It is approved in the United States and many other jurisdictions in two branded presentations — one indicated for glycaemic control in type 2 diabetes and one indicated for chronic weight management — and every question about whether it is appropriate for a given person belongs with a prescribing clinician. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision.

The sections below organise the published evidence by outcome domain: what was measured, in whom, by what study design, and in which direction the result went. Where a finding came from a mechanistic or review paper rather than a clinical endpoint trial, that is labelled. A broader background on the molecule is available in the liraglutide overview.

Where liraglutide came from

A 2019 review in Frontiers in Endocrinology described the medicinal-chemistry work behind liraglutide and semaglutide, including fatty-acid acylation that promotes albumin binding and extends circulating half-life, which is what made once-daily subcutaneous administration feasible for liraglutide (PMID 31031702). That review is a development history rather than an efficacy study, and the authors framed the two molecules as successive steps in the same engineering programme (PMID 31031702).

Body weight in adults: what the trials measured

The most frequently cited adult weight trial was a 56-week double-blind randomised controlled trial of liraglutide 3.0 mg published in the New England Journal of Medicine, in which 3,731 adults without type 2 diabetes lost a mean of 8.4 kg on liraglutide versus 2.8 kg on placebo, a difference of 5.6 kg (PMID 26132939). In the same trial, researchers reported that 63.2% of liraglutide participants and 27.1% of placebo participants lost at least 5% of baseline body weight, and that 33.1% versus 10.6% lost more than 10% (PMID 26132939).

Those figures are group means from a trial that combined the drug with lifestyle counselling, and the study reported considerable variability around them (PMID 26132939). Nothing in the trial design allows an individual outcome to be predicted from the average.

Body weight and BMI in children and adolescents

A randomised, placebo-controlled trial of liraglutide 3.0 mg in adolescents aged 12 to under 18 years with obesity, published in 2020, reported a greater reduction in BMI standard-deviation score with liraglutide than with placebo at week 56, and reported partial regression of the effect during the 26-week off-treatment follow-up period (PMID 32233338).

A later randomised trial extended testing to children aged 6 to under 12 years with obesity, where the study reported a greater reduction in BMI at week 56 in the liraglutide group than in the placebo group, with BMI increasing in the placebo group over the same period (PMID 39258838). Both paediatric trials were placebo-controlled and both were conducted alongside lifestyle therapy, and both reported more adverse events in the liraglutide arms than in placebo (PMID 32233338, PMID 39258838).

Kidney outcomes in type 2 diabetes

Renal outcomes were examined as a prespecified secondary analysis of a large cardiovascular outcomes trial in type 2 diabetes, in which 9,340 participants were randomised to liraglutide or placebo and followed for a median of 3.84 years; the composite renal outcome occurred in 268 of 4,668 liraglutide participants versus 337 of 4,672 placebo participants (hazard ratio 0.78), a difference the researchers attributed mainly to fewer cases of new-onset persistent macroalbuminuria (PMID 28854085). The study described this as a secondary analysis in a population already at high cardiovascular risk, not a dedicated nephropathy trial (PMID 28854085).

Liver: non-alcoholic steatohepatitis

The LEAN study was a multicentre, double-blind, randomised, placebo-controlled phase 2 trial of liraglutide 1.8 mg daily for 48 weeks in patients with biopsy-confirmed non-alcoholic steatohepatitis, in which 9 of 23 patients (39%) in the liraglutide group had resolution of definite steatohepatitis on end-of-treatment biopsy versus 2 of 22 (9%) on placebo (PMID 26608256). The investigators described the trial as a small phase 2 signal-finding study requiring confirmation in larger trials, and reported gastrointestinal events more often in the liraglutide group (PMID 26608256).

Metabolic syndrome, abdominal obesity and inflammation

A randomised controlled trial published in Cardiovascular Diabetology compared exercise, GLP-1 receptor agonist treatment, their combination and placebo after a diet-induced weight loss phase, and reported that the combination reduced metabolic syndrome severity, abdominal obesity and markers of inflammation more than either intervention alone (PMID 36841762). That design is one of the few that isolated what the drug added on top of structured exercise rather than testing it in isolation (PMID 36841762).

How liraglutide compared with other GLP-1 medicines

Head-to-head and network evidence consistently placed liraglutide behind the newer long-acting agents on weight endpoints. The STEP 8 randomised clinical trial compared once-weekly semaglutide 2.4 mg with once-daily liraglutide 3.0 mg in adults with overweight or obesity without diabetes over 68 weeks and reported mean body-weight change of −15.8% with semaglutide versus −6.4% with liraglutide (PMID 35015037).

A 2025 systematic review and meta-analysis comparing semaglutide with liraglutide, dulaglutide and tirzepatide reported pooled efficacy differences across the class rather than a single winner for every outcome, and the authors noted heterogeneity between the included trials (PMID 40444045). A Bayesian network meta-analysis of randomised controlled trials in obesity without type 2 diabetes reported the same general ordering while also assessing comparative safety (PMID 41820778).

What studies reported after treatment stopped

A 2025 narrative review of randomised studies examined weight trajectories after interruption of liraglutide, semaglutide or tirzepatide and reported weight regain following discontinuation across the agents reviewed (PMID 40507553). The adolescent trial similarly reported that the BMI difference narrowed after treatment stopped during off-drug follow-up (PMID 32233338).

Mechanisms described in reviews

A 2024 review in Frontiers in Nutrition summarised molecular mechanisms proposed for semaglutide and liraglutide in obesity, including GLP-1 receptor signalling affecting appetite regulation, gastric emptying and energy intake (PMID 38742021). Much of the mechanistic literature summarised there derives from preclinical and cell-based work, and the review presented it as explanatory background rather than clinical outcome evidence (PMID 38742021).

Claims this evidence set does not support

Several outcomes commonly associated with GLP-1 medicines in general discussion were not endpoints in the studies cited here. The trials and reviews referenced on this page measured body weight, BMI, metabolic syndrome components, renal composite outcomes and liver histology (PMID 26132939, PMID 28854085, PMID 26608256). They did not report on cognition, longevity, athletic performance, muscle growth or cosmetic outcomes, so no direction of effect can be drawn from them for those domains.

• Body composition detail: the adult weight trial reported total body weight and categorical weight-loss thresholds rather than compartment-level body composition (PMID 26132939).
• Durability without treatment: the review of randomised discontinuation data reported regain rather than sustained benefit off drug (PMID 40507553).
• Liver endpoints beyond phase 2: the steatohepatitis evidence came from a small phase 2 trial, not a confirmatory phase 3 programme (PMID 26608256).

Adverse Events: What Studies Report

Gastrointestinal effects dominated the reported safety data. In the 56-week adult weight trial, researchers reported that the most common adverse events were mild-to-moderate nausea and diarrhoea, with serious adverse events in 6.2% of liraglutide participants versus 5.0% on placebo (PMID 26132939). The phase 2 steatohepatitis trial reported gastrointestinal events including diarrhoea, constipation and loss of appetite more frequently with liraglutide than with placebo (PMID 26608256).

In the adolescent trial, the study reported more gastrointestinal adverse events and more treatment discontinuations due to adverse events in the liraglutide group than in the placebo group (PMID 32233338), and the trial in children aged 6 to under 12 years likewise reported more frequent adverse events, predominantly gastrointestinal, with liraglutide (PMID 39258838). Comparative safety across the class was also assessed in the Bayesian network meta-analysis of randomised trials in obesity without type 2 diabetes (PMID 41820778). Safety information from trials does not substitute for the approved product labelling or for an individual clinical assessment.

Reading these findings in context

Every number above came from a controlled research setting with defined eligibility criteria, protocol-driven titration and concurrent lifestyle intervention, and the trials reported group averages rather than individual outcomes (PMID 26132939, PMID 35015037). Liraglutide is a prescription-only medicine in the jurisdictions where it is approved; decisions about eligibility, monitoring, interactions and continuation are clinical decisions made with a licensed prescriber, and this page makes no recommendation of any kind.

References

• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (The New England Journal of Medicine, 2015)
• A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity (The New England Journal of Medicine, 2020)
• Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial (The New England Journal of Medicine, 2025)
• Liraglutide and Renal Outcomes in Type 2 Diabetes (The New England Journal of Medicine, 2017)
• Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study (Lancet, 2016)
• Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial (Cardiovascular Diabetology, 2023)
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial (JAMA, 2022)
• Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis (Frontiers in Pharmacology, 2025)
• Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials (Advances in Therapy, 2026)
• Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies (Journal of Clinical Medicine, 2025)
• Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity (Frontiers in Nutrition, 2024)